All In Biotech

Drug Trial Radar · NCT04609111

ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study

ShorT and OPtimal Duration of Dual AntiPlatelet Therapy Study After Everolimus-eluting Cobalt-chromium Stent-3

Last checked: Nov 20, 2026Latest source record: Jun 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 6,002 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

6,002

Actual

Start

Jan 29, 2021

Primary completion

Dec 31, 2023

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Kyoto University, Graduate School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to explore the benefit of the prasugrel monotherapy without aspirin as compared with the 1-month dual therapy with aspirin and prasugrel in terms of reducing bleeding events after percutaneous coronary intervention (PCI) using cobalt-chromium everolimus-eluting stents (CoCr-EES, XienceTM) in patients with high bleeding risk or under the acute coronary syndrome patients.

Conditions

  • Acute Coronary Syndrome

Interventions

  • No aspirinDrug

    1-month prasugrel monotherapy followed by clopidogrel monotherapy

  • 1-month DAPTDrug

    1-month dual antiplatelet therapy comprising of aspirin and prasugrel followed by aspirin monotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major bleedingTime frame: 1 month
  2. Cardiovascular composite endpointTime frame: 1 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kyoto University Graduate School of Medicine

    Kyoto, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.